echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > All human monoclonal antibody injection of Watson biological recombinant anti TNF - α obtained the approval of clinical trial in Korea

    All human monoclonal antibody injection of Watson biological recombinant anti TNF - α obtained the approval of clinical trial in Korea

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Jiahe biopharmaceutical Co., Ltd., a subsidiary of Watson biology, has obtained the clinical trial approval document issued by the Ministry of food and drug safety of South Korea for its independently developed product "recombinant anti-tumor necrosis factor - α all human monoclonal antibody injection"

    According to reports, the approved drug is a monoclonal antibody biological similar drug independently developed by Jiahe biology

    Its original research drug, Humira ® (Chinese trade name xiumeile, Chinese and English common names are adalimumab and adalimumab respectively), was first developed and listed by Abbott in 2003, and its global sales reached 106 in 2013 Billion US dollars, is the world's largest single product sales of drugs

    "Recombinant anti TNF - α all human monoclonal antibody injection" is a kind of all human monoclonal antibody drug, which can inhibit the activation of TNF - α by binding with TNF - α Receptor, so as to inhibit the inflammatory response related to autoimmune diseases

    The approved clinical indications mainly include moderate and severe active rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis arthritis, mandatory spondylitis, Crohn's disease, plaque psoriasis and ulcerative colitis and other autoimmune diseases

    In May 2013, Jiahe biology signed a cooperation agreement on overseas development and promotion of the product with Korea biocnd company, and at the end of 2013, biocnd company submitted the application for clinical trial of the product in Korea to the Ministry of food and drug safety (MFDs) of Korea

    Industry insiders said that in recent years, South Korea has taken biomedical as a new engine of domestic economic development, which has led to South Korea quickly becoming one of the hot spots of global drug clinical trials

    From 2004 to 2009, the number of drug clinical trials implemented in South Korea has doubled

    According to the statistics of clinical trials.gov, according to the number of drug trials in countries around the world, South Korea has been ranked from 34th to 12th

    However, Korea implements a very strict clinical trial evaluation method, which requires that all new chemical entities and biological products exported to Korea must provide clinical trial data in Korea without considering clinical trial data in other Asian countries, which greatly increases the cost of imported drugs

    And after the clinical trial is completed, enterprises are required to submit complete production data in the process of drug approval

    Therefore, Watson bio's product has a long way to go before it is officially launched in South Korea

    The company also pointed out in the announcement that the approval of clinical trial of Jiahe biology "recombinant anti-tumor necrosis factor - α all human monoclonal antibody injection" in Korea will not affect the company's recent performance.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.